Needham Reiterates Buy on Ionis Pharmaceuticals, Maintains $60 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a Buy rating on Ionis Pharmaceuticals (NASDAQ:IONS) and maintained a $60 price target.
April 09, 2024 | 10:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Joseph Stringer reiterated a Buy rating on Ionis Pharmaceuticals with a $60 price target.
The reiteration of a Buy rating and maintenance of a $60 price target by a reputable analyst could positively influence investor sentiment towards Ionis Pharmaceuticals, potentially driving up its stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100